Literature DB >> 26215510

Chronic kidney disease: Reductions in FGF-23 levels associated with improved outcomes.

Anna Jovanovich1, Michel Chonchol2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26215510     DOI: 10.1038/nrneph.2015.125

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 3.  Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?

Authors:  Pieter Evenepoel; Mariano Rodriguez; Markus Ketteler
Journal:  Semin Nephrol       Date:  2014-02-18       Impact factor: 5.299

4.  Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Authors:  Sharon M Moe; Glenn M Chertow; Patrick S Parfrey; Yumi Kubo; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; David C Wheeler; Maria Stolina; Bastian Dehmel; William G Goodman; Jürgen Floege
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

5.  FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.

Authors:  Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2011-09-07       Impact factor: 10.121

6.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Authors:  Orlando Gutierrez; Tamara Isakova; Eugene Rhee; Anand Shah; Julie Holmes; Gina Collerone; Harald Jüppner; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2005-05-25       Impact factor: 10.121

7.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Authors:  James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

8.  Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.

Authors:  Heng Jung Hsu; Mai-Szu Wu
Journal:  Am J Med Sci       Date:  2009-02       Impact factor: 2.378

9.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl       Date:  2009-08       Impact factor: 10.545

10.  United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease.

Authors:  Allan J Collins; Robert N Foley; David T Gilbertson; Shu-Cheng Chen
Journal:  Kidney Int Suppl (2011)       Date:  2015-06
  10 in total
  1 in total

1.  Meta-Analysis of the Association between Fibroblast Growth Factor 23 and Mortality and Cardiovascular Events in Hemodialysis Patients.

Authors:  Shaohui Gao; Jinsheng Xu; Shenglei Zhang; Jingjing Jin
Journal:  Blood Purif       Date:  2019-01-30       Impact factor: 2.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.